睿知中国医院研究地图
候选清单

正在招募胰腺癌I/II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer

ClinicalTrials.gov 上登记的一项胰腺癌开放试验,由海军军医大学第一附属医院(长海医院)牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方海军军医大学第一附属医院(长海医院)Changhai Hospital上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT04146298,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 4

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(4 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Patients with measurable and pathologically confirmed advanced pancreatic cancer, including metastatic pancreatic cancer (who have received standard chemotherapy) and recurrent pancreatic cancer (who have received surgery and adjuvant chemotherapy previously).

    入选标准第 1 条

  3. Absolute neutrophil count of at least 1000/mm\^3.

    入选标准第 12 条

    Platelet count of at least 100,000/mm\^3.

    入选标准第 14 条

    Hemoglobin > 8.0 g/dL.

    入选标准第 15 条

    Serum ALT/AST less than or equal to 3.0 x ULN.

    入选标准第 17 条

    Total bilirubin less than or equal to 1.5 mg/dL, unless the patient has Gilbert's Syndrome in which case total bilirubin must be less than or equal to 3.0 mg/dL.

    入选标准第 18 条

    Serum creatinine less than or equal to 1.6 mg/dL.

    入选标准第 19 条

  4. Women who are pregnant or breastfeeding.

    排除标准第 1 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);既往治疗;日常活动能力;影像与可测量病灶;试验排除的其他疾病。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT04146298,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Patients with measurable and pathologically confirmed advanced pancreatic cancer, including metastatic pancreatic cancer (who have received standard chemotherapy) and recurrent pancreatic cancer (who have received surgery and adjuvant chemotherapy previously).
  2. Patient's tumor must express the KRAS G12V mutation, or a G12V mutation in HRAS or NRAS, as determined by DNA or RNA sequencing methods.
  3. Patients must be HLA-A*11:01.
  4. Patients with brain metastasis may be eligible if they are asymptomatic and there are fewer than 3 brain lesions that are each less than 1 cm in diameter.
  5. Patients between 18 to 75 years old are eligible.
  6. Patients should have good clinical performance status (ECOG 0 or 1).
  7. Patients must practice birth control once enrolled into the study and for up to four months after therapy.
  8. Patients must be seronegative for HIV antibody.
  9. Patients must be seronegative for hepatitis B surface antigen and core antibody (or HBV non-detectable by QPCR).
  10. Patients must be seronegative for hepatitis C antibody (or HCV non-detectable by QPCR).
  11. Baseline hematology criteria:
  12. Absolute neutrophil count of at least 1000/mm\^3.
  13. White blood cell count of at least 3000/mm\^3.
  14. Platelet count of at least 100,000/mm\^3.
  15. Hemoglobin > 8.0 g/dL.
  16. Baseline chemistry criteria:
  17. Serum ALT/AST less than or equal to 3.0 x ULN.
  18. Total bilirubin less than or equal to 1.5 mg/dL, unless the patient has Gilbert's Syndrome in which case total bilirubin must be less than or equal to 3.0 mg/dL.
  19. Serum creatinine less than or equal to 1.6 mg/dL.
  20. Anticipated lifespan greater than 12 weeks.
  21. Patients must be willing and able to comply with all study-related procedures and follow-up requirements.
  22. Patients must be able to understand and sign a written Informed Consent Document as well as a durable power of attorney.

排除标准:Exclusion Criteria:

  1. Women who are pregnant or breastfeeding.
  2. Patients with any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease or HIV).
  3. Patients with active systemic infections, coagulation disorders, or any other major medical illnesses.
  4. Patients with concurrent opportunistic infections.
  5. Patients on concurrent systemic steroid therapy.
  6. Patients with a history of severe immediate hypersensitivity reaction to any of the medicines used in this study (e.g., cyclophosphamide, fludarabine).
  7. Patients with active coronary ischemic symptoms.
  8. Patients who are receiving any other investigational agents.

引自 ClinicalTrials.gov, NCT04146298, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT04146298,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT04146298